Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma

Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Delfau-Larue, Marie-Hélène ORCID: https://orcid.org/0000-0002-8010-2343; Macintyre, Elizabeth; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Stilgenbauer, Stephan; Vehling-Kaiser, Ursula; Salles, Gilles ORCID: https://orcid.org/0000-0002-9541-8666; Thieblemont, Catherine ORCID: https://orcid.org/0000-0002-9941-2448; Tilly, Hervé ORCID: https://orcid.org/0000-0001-7022-5246; Wirths, Stefan ORCID: https://orcid.org/0000-0003-2494-9862; Feugier, Pierre; Hübel, Kai; Schmidt, Christian; Ribrag, Vincent; Kluin-Nelemans, Johanna C. ORCID: https://orcid.org/0000-0003-2617-9427; Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249 und Pott, Christiane ORCID: https://orcid.org/0009-0005-9260-8340 (2023): Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma. Results From the European Mantle Cell Lymphoma Elderly Trial. In: Journal of Clinical Oncology, Vol. 42, No. 5: pp. 538-549

Full text not available from 'Open Access LMU'.

DOI: 10.1200/JCO.23.00899

Item Type:	Journal article
Faculties:	Medicine > Institute for Medical Information Processing, Biometry and Epidemiology Medicine > Medical Center of the University of Munich > Medical Clinic and Outpatient Clinic III (Oncology)
Subjects:	600 Technology > 610 Medicine and health
ISSN:	0732-183X
Language:	English
Item ID:	108512
Date Deposited:	04. Jan 2024 15:05
Last Modified:	04. Mar 2024 08:50

Actions (login required)

View Item